Cardarine GW501516 Powder 1g

Description

Cardarine GW501516 Powder — Research Overview

Cardarine (GW501516, GW1516) is a PPARδ (peroxisome proliferator-activated receptor delta) agonist originally developed by GlaxoSmithKline and Ligand Pharmaceuticals. Although not a SARM by mechanism (PPARδ is a nuclear receptor in the fatty acid oxidation pathway, not the androgen receptor), it is frequently categorised alongside SARMs in research compound literature due to similar distribution channels and research applications.

Mechanism of Action

GW501516 activates PPARδ, a nuclear receptor that regulates genes involved in fatty acid catabolism, mitochondrial biogenesis, and glucose utilisation. PPARδ activation in skeletal muscle promotes the type I (slow-twitch, oxidative) fibre phenotype, increases fatty acid oxidation, reduces intramyocellular lipid accumulation, and upregulates GLUT4 expression. In adipose tissue, it promotes fat mobilisation and reduces lipogenesis.

Research Applications

GW501516 is widely used in: metabolic syndrome models (insulin resistance, dyslipidaemia), exercise biology and “exercise mimetic” research, cardiovascular disease models (HDL elevation, endothelial function), and skeletal muscle fibre-type transition studies. The “exercise-in-a-pill” characterisation in rodent studies (Narkar et al., Cell 2008) established GW501516 as a key tool compound in metabolic biology.

Powder Format for Research

Powder is the preferred format for in vitro cell culture (adipocytes, myocytes, hepatocytes) and rodent metabolic studies. Soluble in DMSO (≥50mg/mL). Standard in vivo dosing: 5–10mg/kg/day oral gavage in rodent studies.

Purity: ≥98% (HPLC verified) | Format: Lyophilised powder | Quantity: 1g

For research use only. Not for human consumption.